Drug intelligence / Profile preview

MSC-CDV

Development stage: Preclinical
Lead developer: MDimune

Overview

**MSC-CDV** is a nanovesicle-based therapeutic product derived from mesenchymal stem cells (MSCs), developed by MDimune for the treatment of inflammatory bowel diseases (IBD). It leverages MSC-derived nanovesicles to modulate inflammation and promote tissue repair, representing one of MDimune's most characterized pipeline candidates with potential in gastrointestinal disorders through targeted delivery and immunomodulatory effects.

Beyond the preview

Go deeper on MSC-CDV.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MSC-CDV.

Explore the full profile